Inhibition of the expression of TGF-β1 and CTGF in human mesangial cells by exendin-4, a glucagon-like peptide-1receptor agonist

Cellular Physiology and Biochemistry

Volumn 30, Issue 3, 2012, Pages 749-757

  Li, Wenbin ^a   Cui, Meiyu ^a   Wei, Yong ^a   Kong, Xianglei ^a   Tang, Lijun ^a   Xu, Dongmei ^a  

^a THE FIRST AFFILIATED HOSPITAL OF SHANDONG FIRST MEDICAL UNIVERSITY   (China)

Author keywords

Connective tissue growth factor (CTGF); Exendin 4; Human mesangial cells (HMCs)

Indexed keywords

ADENYLATE CYCLASE; CONNECTIVE TISSUE GROWTH FACTOR; CYCLIC AMP; EXENDIN 4; MESSENGER RNA; TRANSFORMING GROWTH FACTOR BETA1;

ARTICLE; CELL PROLIFERATION; HUMAN; HUMAN CELL; MESANGIUM CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN SYNTHESIS; RENAL PROTECTION; SIGNAL TRANSDUCTION; UPREGULATION;

EID: 84865227510     PISSN: 10158987     EISSN: 14219778     Source Type: Journal    
DOI: 10.1159/000341454     Document Type: Article

References (39)

1. Chen Y, Blom IE, Sa S, Goldschmeding R, Abraham DJ, Leask A: CTGF expression in mesangial cells: involvement of SMADs, MAP kinase, and PKC. Kidney Int 2002;62:1149-1159.
2. Moussad EEA, Brigstock DA: Connective tissue growth factor: What's in a name? Molec Genet Metab 2000;71:276-292.
3. Denton C, Abraham DJ:Transforming growth factor-beta and connective tissue growth factor: Key cytokines in scleroderma pathogenesis. Curr Opin Rheumatol 2001;13:505-511.
4. Wahab NA, Yevdokimova N, Weston BS, Roberts T, Li XJ, Brinkman H, Mason RM: Role of connective tissue growth factor in the pathogenesis of diabetic nephropathy. Biochem J 2001;359:77-87.
5. Wang S, Denichilo M, Brubaker C, Hirschberg R: Connective tissue growth factor in tubulointerstitial injury of diabetic nephropathy. Kidney Int 2001;60:96-105.
6. Blom IE, van Dijk AJ, Wieten L, Duran K, Ito Y, Kleij L, deNichilo M, Rabelink TJ, Weening JJ, Aten J, Goldschmeding R: In vitro evidence for differential involvement of CTGF, TGFb, and PDGF-BB in mesangial response to injury. Nephrol Dial Transplant 2001;16:1139-1148.
7. Kamiński KA, Szepietowska B, Bonda T, Kozuch M, Mencel J, Makowski A, Sobo lewski K, Kovalchuk O, Chyczewski L, Szelachowska M, Górska M, Musia WJ, Winnicka MM: CCN2 protein is an announcing marker for cardiac remodeling following STZ-induced moderate hyperglycemia in mice. Pharmacol Rep 2009;61:496-503.
8. Wang XD, Shaw S, Amiri F, Eaton DC, Marrero MB: Inhibition of the JAK/STAT signaling pathway prevents the high glucoseinduced increase in TGF-ß and fibronectin synthesis in mesangial cells. Diabetes 2002;51:3505-3509.
9. Yamabe H, Osawa H, Kaizuka M, Tsunoda S, Shirato K, Tateyama F, Okumura K: Platelet-derived growth factor, basic fibroblast growth factor, and interferon increase type IV collagen production in human fetal mesangial cells via a transforming growth factor-ß-dependent mechanism. Nephrol Dial Transplant 2000;15:872-876.
10. Leask A, Sa S, Holmes A, Shiwen X, Black CM, Abraham DJ: The control of ccn2 (ctgf) gene expression in normal and scleroderma fibroblasts. Mol Pathol 2001;54:180-183.
11. Ban K, Noyan-Ashraf MH, Hoefer J, Bolz SS, Drucker DJ, Husain M: Cardioprotective and vasodilatory actions of glucagon-like peptide 1 receptor are mediated through both glucagon-like peptide 1 receptordependent and-independent pathways. Circulation 2008;117:2340-2350.
12. Bullock BP, Heller RS, Habener JF: Tissue distribution of messenger ribonucleic acid encoding the rat glucagon-like peptide-1 receptor. Endocrinology 1996;137:2968-2978.
13. Nystrom T, Gutniak MK, Zhang F, Holst JJ, Ahrén B, Sjholm A: Effects of glucagon-like peptide-1 on endothelial function in type 2 diabetes patients with stable coronary artery disease. Am J Physiol Endocrinol Metab 2004;287:1209-1215.
14. Park CW, Kim HW, Ko SH, Lim JH, Ryu GR, Chung HW, Han SW, Shin SJ, Bang BK, Breyer MD, Chang YS: Long-term treatment of glucagon-like peptide-1 analog exendin-4 ameliorates diabetic nephropathy through improving metabolic anomalies in db/db mice. J Am Soc Nephrol 2007;18:1227-1238.
15. Drucker DJ: The biology of incretin hormones. Cell Metab 2006;3:153-165.
16. Kodera R, Shikata K, Kataoka HU, Takatsuka T, Miyamoto S, Sasaki M, Kajitani N, Nishishita S, Sarai K, Hirota D, Sato C, Ogawa D, Makino H: Glucagon-like peptide-1 receptor agonist ameliorates renal injury through its anti-inflammatory action without lowering blood glucose level in a rat model of type 1 diabetes. Diabetologia 2011;54:965-78.
17. Chaykovska L, von Websky K, Rahnenführer J, Alter M, Heiden S, Fuchs H, Runge F, Klein T, Hocher B: Effects of DPP-4 inhibitors on the heart in a rat model of uremic cardiomyopathy. PLoS One 2011;6:27861.
18. Oeseburg H, de Boer RA, Buikema H, van der Harst P, van Gilst WH, Silljé HH: Glucagon-Like peptide 1 prevents peactive oxygen species-induced endothelial cell senescence through the activation of protein kinase A. Arterioscler Thromb Vasc Biol 2010;30:1407-1414.
19. Sharma K, Ziyadeh FN: Hyperglycemia and diabetic kidney disease, the case for transforming growth factor-ß as a key mediator. Diabetes 1995;44:439-446.
20. Border WA, Yahamoto T, Noble NA: Transforming growth factor-ß in diabetic nephropathy. Diabetes Metab Rev1996;12:309-339.
21. Yamamoto T, Noble NA, Cohen AH, Nast CC, Hishida A, Gold LI, Border WA: Expression of transforming growth factor-ß isoforms in human glomerular diseases. Kidney Int 1996;49:461-469.
22. Ziyadeh FN, Hoffman BB, Han DC, Iglesias-De La Cruz MC, Hong SW, Isono M, Chen S, McGowan TA, Sharma K: Long term prevention of renal insufficiency, excess matrix gene expression, and glomerular mesangial matrix expansion by treatment with monoclonal anti-transforming growth factor-ß antibody in db/db diabetic mice. Proc Natl Acad Sci USA 2000;97:8015-8020.
23. Roestenberg P, van Nieuwenhoven FA, Joles JA, Trischberger C, Martens PP, Oliver N, Aten J, Hppener JW, Goldschmeding R: Temporal expression profile and distribution pattern indicate a role of connective tissue growth factor in diabetic nephropathy in mice. Am J Physiol Renal Physiol 2006;209:1344-1354.
24. Grotendorst GR: Connective tissue growth factor: a mediator of TGF-ß action on fibroblasts. Cytokine Growth Factor Rev 1997;8:171-179.
25. Zhang SX, Wang JJ, Lu K, Mott R, Longeras R, Ma JX: Therapeutic Potential of Angiostatin in Diabetic Nephropathy. J Am Soc Nephrol 2006;17:475-486.
26. Greig NH, Holloway HW, De Ore KA, Jani D, Wang Y, Zhou J, Garant MJ, Egan JM: Once daily injection of exendin-4 to diabetic mice achieves long term beneficial effects on blood glucose concentrations. Diabetologia 1999;42:45-50.
27. Kolterman OG, Buse JB, Fineman MS, Gaines E, Heintz S, Bicsak TA, Taylor K, Kim D, Aisporna M, Wang Y, Baron AD: Synthetic exendin-4 (exenatide) significantly reduces postprandial and fasting plasma glucose in subjects with type 2 diabetes. J Clin Endocrinol Metab 2003;88:3082-3089.
28. Parkes DG, Pittner R, Jodka C, Smith P, Young A: Insulinotropic actions of exendin-4 and glucagon-like peptide-1 in vivo and in vitro. Metabolism 2001;50:583-589.
29. Dupré J, Behme MT, McDonald TJ: Exendin-4 normalized postcibal glycemic excursions in type 1 diabetes. J Clin Endocrinol Metab 2004;89:3469-3473.
30. Szayna M, Doyle ME, Betkey JA, Holloway HW, Spencer RG, Greig NH, Egan JM: Exendin-4 decelerates food intake, weight gain, and fat deposition in Zucker rats. Endocrinology 2000;141:1936-1941.
31. Wheeler MB, Lu M, Dillon JS, Leng XH, Chen C, Boyd AE 3rd: Functional expression of the rat glucagon-like peptide 1 receptor, evidence for coupling to both adeny 1 cyclase and phospholipase-C. Endocriology 1993;133:57-62.
32. Kodera R, Shikata K, Kataoka HU, Takatsuka T, Miyamoto S, Sasaki M, Kajitani N, Nishishita S, Sarai K, Hirota D, Sato C, Ogawa D, Makino H: Glucagon-like peptide-1 receptor agonist ameliorates renal injury through its anti-inflammatory action without lowering blood glucose level in a rat model of type 1 diabetes. Makino Diabetologia 2011;54:965-978.
33. Ishibashia Y, Nishinoa Y, Matsuia T, Yamagishi S: Glucagon-like peptide-1 suppresses advanced glycation end product-induced monocyte chemoattractant protein-1 expression in mesangial cells by reducing advanced glycation end product receptor level. Metabolism clinical and experimental 2011;60:1271-1277.
34. Gedulin BR, Smith P, Prickett KS, Tryon M, Barnhill S, Reynolds J, Nielsen LL, Parkes DG, Young AA: Dose-response for glycaemic and metabolic changes 28 days after single injection of long-acting release exenatide in diabetic fatty Zucker rats. Diabetologia 2005;48:1380-1385.
35. Kolterman OG, Kim DD, Shen L, Ruggles JA, Nielsen LL, Fineman MS, Baron AD: Pharmacokinetics, pharmacodynamics, and safety of exenatide in patients with type 2 diabetes mellitus. Am J Health Syst Pharm 2005;62:173-181.
36. Lam S, van der Geest RN, Verhagen NA, Daha MR, van Kooten C: Secretion of collagen type IV by human renal fibroblasts is increased by high glucose via a TGF-ß independent pathway. Nephrol Dial Transplant 2004;19:1694-1701.
37. Dorado F, Velasco S, Esparís-Ogando A, Pericacho M, Pandiella A, Silva J, López-Novoa JM, Rodríguez-Barbero A: The mitogen-activated protein kinase Erk5 mediates human mesangial cell activation. Nephrol Dial Transplant 2008;23:3403-3411.
38. Brubaker PL, Drucker DJ: Minireview: glucagon-like peptides regulate cell proliferation and apoptosis in the pancreas, gut, and central nervous system. Endocrinology 2004;145:2653-2659.
39. Arakawa M, Mita T, Azuma K, Ebato C, Goto H, Nomiyama T, Fujitani Y, Hirose T, Kawamori R, Watada H: Inhibition of monocyte adhesion to endothelial cells and attenuation of atherosclerotic lesion by a glucagon-like peptide-1 receptor agonist, exendin-4. Diabetes 2010;59:1030-1037.